Improved Screening For Prostate Cancer

April 2017

Cancer

Country of origin: UK

Prostate-specific antigen (PSA) is widely used to detect prostate cancer. The low positive predictive value of elevated PSA results in large numbers of unnecessary prostate biopsies. Researchers set out to determine whether a multivariable model including four kallikrein forms (total, free, and intact PSA, and human kallikrein 2 (hK2)) could predict prostate biopsy outcome in previously unscreened men with elevated total PSA.

The study cohort comprised 740 men in Göteborg, Sweden, undergoing biopsy during the first round of the European Randomised study of Screening for Prostate Cancer. The researchers calculated the area-under-the-curve (AUC) for predicting prostate cancer at biopsy. AUCs for a model including age and PSA (the 'laboratory' model) and age, PSA and digital rectal exam (the 'clinical' model) were compared with those for models that also included additional kallikreins.

Addition of free and intact PSA and hK2 improved AUC from 0.68 to 0.83 and from 0.72 to 0.84, for the laboratory and clinical models respectively. Using a 20% risk of prostate cancer as the threshold for biopsy would have reduced the number of biopsies by 424 (57%) and missed only 31 out of 152 low-grade and 3 out of 40 high-grade cancers.

The research concludes that multiple kallikrein forms measured in blood can predict the result of biopsy in previously unscreened men with elevated PSA. A multivariable model can determine which men should be advised to undergo biopsy and which might be advised to continue screening, but defer biopsy until there was stronger evidence of malignancy.

'A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomised Study of Prostate Cancer Screening in Göteborg, Sweden' is available online.

Resources

inPractice® Oncology April 2018 inPractice® Oncology is the only point-of-care clinical reference designed to meet the unique needs of specialists. Full...
Cancer Research Network Measures March 2018 Following a period of consultation Cancer Research Network Measures have been issued by the Department of Health as part of...
Orlive Surgical Broadcasts February 2018 Orlive is a trusted world resource in surgical broadcasting for physians, surgeons and caregivers.
ONCO Assist January 2018 Oncoassist app was designed by oncologists keeping in mind the clinical needs that arise while treating cancer patients....
Cancer.net mobile by ASCO January 2018 The Cancer.net mobile app by ASCO provides info on 120 types of cancer, including treatment information, managing side...
Chemo Calendar January 2018 Chemo Calendar app by Health Monitor Network can track the patient’s symptoms. It captures key symptoms like temperature,...
Cancer Navigator January 2018 Cancer Navigator app was developed by MD Acuity, LLC. The app tracks symptoms during cancer treatment in a graphic...
Oncology Nurse Advisor January 2018 Oncology Nurse Advisor is a free, simple to use, medical app that offers oncology nurses the latest news and trends....
Breast Cancer Survivor January 2018 Survivorship encompasses a range of lifestyle approaches to improve wellbeing and survival after a diagnosis of cancer....
Cancer Emergency Response Tool January 2018 The Cancer Emergency Response Tool (CERT) allows cancer patients to rapidly and effectively manage chemotherapy toxicity...
Search by Keyword